Nxera Pharma has received $10 million after a fourth R&D milestone was met in the company’s collaboration with AbbVie.  Nxera and AbbVie entered a multi-target collaboration in 2022 to  leverage Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease.   The fourth milestone relates to the identification of validated and differentiated ‘hit’ […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!